- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01103596
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) (EOLE)
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to ARVs - EOLE
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The purpose of this study is to evaluate, in patients in at least the second PI line, the virological failures under Kaletra® and their consequences on protease and reverse transcriptase genotypes:
- Characterisation of the changes in the resistance genotype in protease and reverse transcriptase,
- Description of the nature and frequency of selected mutations under Kaletra®,
- Description of the predictive factors for mutations and of the impact they could have on other PIs used as maintenance treatment (analysis based on available algorithms).
EOLE is a prospective, multicentre observation study offered to French virology laboratories and involving clinical teams .
It is a transversal study with retrospective data collection for patients meeting the study criteria (virological failure under Kaletra® after at least first line PI treatment).
The study comprises two enrolment periods, separated by an interval of one year, over a period ranging from 2007 to 2011. During this period, virological failures under Kaletra® are identified. For each period, the virologists collect data only from the moment when virological failure under Kaletra® is identified.
The first wave of data collection is now completed and occurred from December 5, 2007 to July 03, 2009.
It is not planned to collect follow-up data in connection with alternative treatment with other antiretrovirals after failure under Kaletra®.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Angers, Frankrike, 49100
- Site Reference ID/Investigator# 27801
-
Bordeaux, Frankrike, 33075
- Site Reference ID/Investigator# 27799
-
Grenoble, Frankrike, 38043
- Site Reference ID/Investigator# 27790
-
Lille, Frankrike, 59037
- Site Reference ID/Investigator# 27796
-
Montpellier, Frankrike, 34295
- Site Reference ID/Investigator# 27786
-
Nantes, Frankrike, 44093
- Site Reference ID/Investigator# 27800
-
Nice, Frankrike, 06202
- Site Reference ID/Investigator# 27798
-
Nimes, Frankrike, 30029
- Site Reference ID/Investigator# 27792
-
Paris, Frankrike, 75013
- Site Reference ID/Investigator# 5595
-
Paris, Frankrike, 75475
- Site Reference ID/Investigator# 27787
-
Paris, Frankrike, 75877
- Site Reference ID/Investigator# 27783
-
Paris, Frankrike, 75908
- Site Reference ID/Investigator# 27802
-
Paris, Frankrike, 75970
- Site Reference ID/Investigator# 27785
-
Paris Cedex 12, Frankrike, 75571
- Site Reference ID/Investigator# 27797
-
Rennes, Frankrike, 35700
- Site Reference ID/Investigator# 27791
-
Rouen, Frankrike, 76000
- Site Reference ID/Investigator# 27788
-
Toulon, Frankrike, 83056
- Site Reference ID/Investigator# 27789
-
Toulouse, Frankrike, 31000
- Site Reference ID/Investigator# 27794
-
Villejuif, Frankrike, 94804
- Site Reference ID/Investigator# 27784
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patient aged under 18 years,
- Pre-treated by at least one protease inhibitor (PI) line,
- In therapeutic failure of the antiretroviral (ARV) maintenance treatment containing Kaletra®.
Therapeutic failure is defined by a viral load> 50 copies/ml after at least three months' treatment with an ARV combination containing Kaletra®, always provided that genotyping is possible .
Exclusion Criteria:
- Patients having received less than three months of Kaletra®,
- Patients for whom the genotype information before starting Kaletra® and at the time of the failure of Kaletra® was not available,
- Patients receiving another protease inhibitor (PI) concomitantly with Kaletra®.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
HIV-infected patients, 1st wave
HIV-infected ARV-experienced patients treated by a combination including Kaletra
|
HIV-infected patients, 2nd wave
HIV-infected ARV-experienced patients treated by a combination including Kaletra
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Genotype for resistance determination
Tidsram: Over the duration of the enrollment for each wave, over a total period of 18 months
|
Over the duration of the enrollment for each wave, over a total period of 18 months
|
Description of the predictive factors for mutations and of the impact they could have on other protease inhibitors (PIs) used as maintenance treatment (analysis based on available algorithms).
Tidsram: Over the duration of the enrollment for each wave, over a total period of 18 months
|
Over the duration of the enrollment for each wave, over a total period of 18 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Isabelle Cohen Codar, PharmD, Abbott France
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P06-124
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektion
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)